1. Introduction {#s0005}
===============

Prospective epidemiological studies of the relationships of endogenous estrogens and other sex hormones with the risk for breast cancer and other diseases have used a variety of assays to measure hormone concentrations in stored samples of serum or plasma. Results have now been published from ∼20 such studies since the late 1980s. The first such studies measured hormones with in-house radioimmunoassays, which generally used a relatively large volume of sample and incorporated an organic extraction step and usually also purification by column chromatography. In the 1990s and 2000s the use of commercially produced immunoassays without extraction or chromatography ("direct assays") became popular with many epidemiologists because these assays were easier to perform (and therefore faster and cheaper) and use less sample than the extraction assays. Some of the direct assays provided results considered adequate for epidemiological studies, which seek mainly to rank individuals rather than to provide accurate estimates of hormone concentrations [@b0005], but the direct methods tend to overestimate concentrations and suffer from cross-reactivity with other steroids [@b0010; @b0015; @b0020; @b0025]. More recently mass spectrometry methods have been developed to measure sex hormones. However, the effect of these assay differences on the associations of sex hormones with other factors is unclear.

The aim of this paper is to describe the relationships of circulating estradiol, estrone and testosterone in postmenopausal women with body mass index (BMI) and breast cancer risk according to the type of assay used, using data from the international Endogenous Hormones and Breast Cancer Collaborative Group [@b0030]. These analyses were prepared for presentation at the workshop "Measuring Estrogen Exposure and Metabolism" in Bethesda, Maryland, March 2014.

2. Methods {#s0010}
==========

2.1. Data collection {#s0015}
--------------------

Studies were eligible for the collaborative re-analysis if they included data on endogenous hormones and breast cancer risk using prospectively collected blood samples from postmenopausal women, as described previously [@b0030; @b0035; @b0040]. Studies were identified by computer-aided literature searches, within relevant review articles, and through discussions with colleagues. The studies included were: Breast and Bone Follow-up to the Fracture Intervention Trial (B∼FIT), USA [@b0045]; CLUE I study "Give us a clue to cancer and heart disease"; Washington County, MD, USA [@b0050]; Cancer Prevention Study-II Nutrition Cohort (CPS-II Nutrition Cohort), USA [@b0055]; Columbia Missouri Serum Bank, MO, USA [@b0060; @b0065]; European Prospective Investigation into Cancer and Nutrition (EPIC), Europe [@b0070]; Guernsey, UK [@b0075]; Malmö/Umeå, Sweden [@b0080]; the Melbourne Collaborative Cohort Study (MCCS), Australia [@b0085]; the Multi-Ethnic Cohort (MEC), USA [@b0090]; Nurses' Health Study (NHS I), USA [@b0095; @b0100]; New York University Women's Health Study (NYU WHS), USA [@b0105; @b0110; @b0115]; Study of Hormones and Diet in the Etiology of Breast Tumors (ORDET), Italy [@b0120]; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial cohort (PLCO), USA [@b0125]; Rancho Bernardo, USA [@b0130]; Radiation Effects Research Foundation (RERF), Japan [@b0135; @b0140]; Study of Osteoporotic Fractures (SOF), USA [@b0145]; United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), UK [@b0150]; and the Women's Health Initiative, Observational Study (WHI-OS), USA [@b0155]. Details of the recruitment of participants, informed consent, and definitions of reproductive variables are in the original publications. Women who were using menopausal hormone therapy or other exogenous sex hormones at the time of blood collection were excluded. Collaborators provided data on concentrations of the hormones estradiol, estrone and testosterone, where available, as well as data on reproductive and anthropometric factors.

2.2. Statistical analysis {#s0020}
-------------------------

For the analyses of hormones and BMI, hormone concentrations were logarithmically transformed to normalize the distributions. Geometric mean hormone concentrations by categories of BMI (calculated as weight in kilograms divided by the square of height in metres and categorized as \<22.5, 22.5--24.9, 25.0--27.4, 27.5--29.9, and 30.0+ kg/m^2^), together with their 95% confidence intervals (CIs), were calculated using the predicted values from analysis of variance models, adjusted for study, age at blood collection (\<55, 55--59, 60--64, 65--69, and 70+ years), and type of menopause (natural, hysterectomy without ovariectomy, bilateral ovariectomy, other or unknown). Partial correlations of estradiol with estrone, testosterone and BMI were computed using study-specific standardized values: (*x~jk~* − *m~j~*)/*s~j~* where *m~j~* and *s~j~* denote the mean and standard deviation of the log-transformed hormone concentrations in study *j* and *x~jk~* is an observation from that study. These standardized values were adjusted for age at blood collection and type of menopause (same categories as above).

Logistic regression conditioned on study-specific matching variables and stratified by study was used to calculate the odds ratio (OR) for breast cancer in relation to serum/plasma hormone concentrations, categorizing women in each study according to the quintiles of hormone concentration for the controls in that study. Adjustments were not made for reproductive, anthropometric or lifestyle risk factors for breast cancer because hormones may mediate the effects of some of these risk factors and previous analyses have shown that adjustments for these risk factors do not materially change the associations of hormones with breast cancer risk in postmenopausal women [@b0030; @b0035]. Most of the original studies used a nested case-control design with controls matched to cases on age and date at blood collection and other relevant factors, and the original matching was retained in the current analyses. Study-specific cut-points were used because the absolute concentrations of hormones vary substantially between studies, partly due to laboratory variation and different assay methods [@b0030]. Tests for linear trend were calculated scoring the fifths as 0, 0.25, 0.5, 0.75, and 1. Heterogeneity in linear trends between studies using different assay methods was assessed using chi-square tests.

For the studies using mass spectrometry, we used the values for unconjugated steroids, where available; for B∼FIT, the mass spectrometry data for estradiol and estrone were available for total steroids, which sums the sulphated, glucuronidated, and unconjugated forms, but not for unconjugated steroids, and are not included in the analyses of steroids by BMI.

All statistical tests were two-sided, and statistical significance was taken as *P* \< 0.05. All analyses were performed using Stata Statistical Software release 10 (Stata Corp., College Station, TX).

3. Results {#s0025}
==========

3.1. Collaborating studies {#s0030}
--------------------------

Eighteen studies contributed data, eleven in the USA, two in the UK, one each in Australia, Italy, Japan and Sweden, and the multi-centre European study EPIC. Geometric mean hormone concentrations in controls are shown in [Table 1](#t0005){ref-type="table"}. For estradiol, six studies had used extraction assays (of which all except Guernsey also used purification by column chromatography), ten studies had used direct assays and four studies had used mass spectrometry assays. Some studies had assay results from more than one phase of follow-up, and in the Columbia study results were available from an early phase of follow-up using direct assays, and from a later time of follow-up using mass spectrometry assays (which included some of the same women as the first follow-up).

3.2. Associations of hormones with BMI {#s0035}
--------------------------------------

[Figs. 1--3](#f0005 f0010 f0015){ref-type="fig"} show the geometric mean hormone concentrations in relation to BMI for estradiol, estrone, and testosterone. Among all controls for estradiol ([Fig. 1](#f0005){ref-type="fig"}) and estrone ([Fig. 2](#f0010){ref-type="fig"}), the mean values were highest for the direct assays and lowest for the mass spectrometry assays, with the extraction assays intermediate. For all assay types the mean concentrations of both estrogens were positively associated with BMI in an approximately linear fashion. Geometric mean concentrations of estradiol were 82%, 31% and 43% higher in obese (BMI ⩾ 30) than in lean (BMI \< 22.5) women for data from extraction, direct and mass spectrometry assays, respectively ([Fig. 1](#f0005){ref-type="fig"}); the corresponding differences for estrone were 57%, 47% and 33% ([Fig. 2](#f0010){ref-type="fig"}). Geometric mean concentrations of testosterone were 12% and 26% higher in obese (BMI ⩾ 30) than in lean (BMI \< 22.5) women for data from extraction and direct assays, respectively, with few data from mass spectrometry ([Fig. 3](#f0015){ref-type="fig"}). The correlations of estradiol with BMI, estrone and testosterone were substantially larger for extraction and mass spectrometry assays than for direct assays ([Table 2](#t0010){ref-type="table"}).

3.3. Associations of hormones with breast cancer risk {#s0040}
-----------------------------------------------------

[Figs. 4--6](#f0020 f0025 f0030){ref-type="fig"} show the associations of the hormones with breast cancer risk. With the exception of testosterone measured by mass spectrometry, for which there was limited data, all measures of the three hormones showed highly statistically significant associations with breast cancer risk, with odds ratios in the highest versus the lowest fifth between 1.46 and 2.66. There was no statistically significant heterogeneity between the different assay methods for the linear associations of each hormone with breast cancer risk.

4. Discussion {#s0045}
=============

The findings from the different assay types (direct, extraction, mass spectrometry) were broadly similar. For all three hormones examined, the largest amount of data was from direct assays. Where enough data were available, all three assay methods showed that BMI was strongly positively associated with the estrogens and moderately positively associated with testosterone, and all three hormones were strongly positively associated with breast cancer risk, regardless of assay method.

The cross-sectional analyses of geometric mean hormone concentrations in relation to BMI showed that on average the direct assays give concentrations that are substantially higher than those from the other assay methods. This difference has been discussed previously, and may be in part due to cross-reactivity between steroids in the direct assays leading to estimated absolute concentrations which may be greater than the true value [@b0010; @b0015; @b0020; @b0025]. The direct assays still showed the expected strong positive associations between BMI and estrogens, but the relative increase in estrogens from lean to obese women was larger for the extraction assays than for the other methods. Conversely the direct assays showed a stronger positive association between testosterone and BMI than the extraction assays. This could perhaps be due to cross-reactivity with estrogenic compounds in the direct assay methods. The correlations of estradiol with BMI, estrone and testosterone were lower for the direct assays than for the extraction and mass spectrometry assays; the reason for this is not known but might again be due to cross-reactivity in the direct assay methods.

The relative risk analyses showed strong positive associations of all three hormones with breast cancer risk, as previously reported by this collaborative group [@b0030] and by subsequent individual studies [@b0045; @b0065; @b0070; @b0080; @b0090; @b0100; @b0115; @b0125; @b0150; @b0155]. There were no striking or statistically significant differences between the results from the different assay methods, but this should be re-evaluated as prospective data accumulate because further data from the more accurate assay methods might reveal differences.

In conclusion, the existing data from prospective studies show that estrogens are strongly associated with breast cancer risk, regardless of the assay method. Direct assays are in general less accurate than extraction assays or mass spectrometry assays [@b0010; @b0015; @b0020; @b0025], and it is possible that the estrogen measures from direct assays may partly reflect cross-reactivity with a number of estrogens and the detection of overall estrogenicity. Recent technological advances have made it possible to apply mass spectrometry methods to small sample volumes in large-scale studies, and future epidemiological and clinical research studies should continue to use the most accurate assays that are feasible within the design characteristics of each study.
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###### 

Age-adjusted geometric mean (95% CI) hormone concentrations for controls, by assay type and study.

  Assay type and study                            Sample   Estradiol (pmol/L)   Estrone (pmol/L)                                         Testosterone (nmol/L)                                                                
  ----------------------------------------------- -------- -------------------- -------------------------------------------------------- ----------------------- ----------------------------------------------------- ------ -------------------
  *Extraction*[a](#tblfn1){ref-type="table-fn"}                                                                                                                                                                               
  CLUE-I                                          Serum    58                   51.9 (44.3--60.8)                                        58                      134 (118--153)                                               
  Guernsey                                        Serum    177                  37.5 (34.2--41.1)                                                                                                                             
  MEC                                             Plasma   302                  30.1 (28.0--32.3)                                        303                     118 (111--125)                                        303    0.79 (0.73--0.85)
  NHS I                                           Plasma   637                  24.9 (23.8--26.2)                                        623                     90 (86--93)                                           626    0.74 (0.71--0.78)
  Rancho Bernardo                                 Plasma   127                  42.3 (38.0--47.1)                                        131                     109 (100--119)                                        128    0.78 (0.70--0.88)
  SOF                                             Serum    365                  21.2 (19.8--22.7)                                        245                     72 (67--77)                                           372    0.62 (0.58--0.67)
  Sweden Malmö/Umeå                               Plasma                                                                                                                                                               230    1.17 (1.07--1.27)
                                                                                                                                                                                                                              
  *Direct*                                                                                                                                                                                                                    
  Columbia (direct assay)                         Serum    133                  48.4 (43.6--53.8)                                        133                     120 (110--131)                                        133    0.55 (0.49--0.61)
  EPIC phase 1                                    Serum    1152                 91.5 (88.2--94.8)                                        1106                    140 (136--145)                                        1319   1.14 (1.10--1.18)
  EPIC phase 2                                    Serum    818                  71.6 (68.6--74.7)                                        575                     140 (135--147)                                        808    1.10 (1.05--1.15)
  Guernsey                                        Serum                                                                                                                                                                178    0.93 (0.84--1.02)
  MCCS                                            Plasma   707                  60.3 (57.6--63.1)                                                                                                                      714    0.66 (0.62--0.69)
  NYU WHS phase 1                                 Serum    558                  84.7 (80.4--89.3)                                        562                     95 (91--99)                                           562    0.63 (0.60--0.67)
  NYU WHS phase 2                                 Serum                                                                                  347                     98 (93--103)                                                 
  ORDET                                           Serum    681                  18.2 (17.4--19.1)                                                                                                                      681    0.78 (0.74--0.82)
  RERF phase 1                                    Serum    45                   69.7 (58.3--83.5)                                                                                                                             
  RERF phase 2                                    Serum    124                  68.0 (61.0--75.8)                                                                                                                      126    0.37 (0.33--0.42)
  Sweden Malmö/Umeå                               Plasma                                                                                 239                     73 (69--78)                                                  
  UKCTOCS                                         Serum    375                  59.4 (55.8--63.2)                                        381                     302 (287--318)                                        377    0.83 (0.78--0.89)
  WHI-OS                                          Serum    436                  41.1 (38.7--43.5)                                                                                                                             
                                                                                                                                                                                                                              
  *Mass spectrometry*                                                                                                                                                                                                         
  B∼FIT                                           Serum    490                  \[40.0 (37.8--42.3)\][b](#tblfn2){ref-type="table-fn"}   490                     \[291 (277--305)\][b](#tblfn2){ref-type="table-fn"}          
  CPS-II Nutrition Cohort                                  249                  24.4 (22.5--26.4)                                        268                     65 (61--69)                                           254    0.68 (0.63--0.74)
  Columbia (mass spec.)                           Serum    217                  11.8 (10.9--12.8)                                        217                     45 (42--48)                                                  
  PLCO                                            Serum    445                  15.9 (15.0--16.8)                                        445                     55 (53--58)                                                  

Abbreviations for study names: B∼FIT = Breast and Bone Follow-up to the Fracture Intervention Trial; CLUE = Washington County, MD study "Give us a clue to cancer and heart disease"; CPS-II = Cancer Prevention Study-II; EPIC = European Prospective Investigation into Cancer and Nutrition; MCCS = Melbourne Collaborative Cohort Study; MEC = Multi-ethnic Cohort; NHS I = Nurses' Health Study I; NYU WHS = New York University Women's Health Study; ORDET = Study of Hormones and Diet in the Etiology of Breast Tumors; PLCO = Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; RERF = Radiation Effects Research Foundation; SOF = Study of Osteoporotic Fractures; UKCTOCS = United Kingdom Collaborative Trial of Ovarian Cancer Screening; WHI-OS = Women's Health Initiative, Observational Study.

Assays which included an extraction step; all except two (Guernsey and Sweden Malmö/Umeå) also included purification by chromatography.

Geometric mean concentrations of estradiol and estrone for B∼FIT are for total steroids, versus unconjugated steroids in the other studies.

###### 

Partial correlations of log estradiol with BMI, log estrone and log testosterone: values standardized to study-specific distribution and adjusted for age and type of menopause.

  Assay               BMI    Estrone   Testosterone
  ------------------- ------ --------- --------------
  Extraction          0.42   0.66      0.40
  Direct              0.19   0.38      0.32
  Mass spectrometry   0.41   0.84      0.41

[^1]: See [Appendix A](#s0050){ref-type="sec"} for members and affiliations of all authors from the Endogenous Hormones and Breast Cancer Collaborative Group.
